Tumour necrosis factor-α production in fibrosing alveolitis is macrophage subset specific by Pantelidis, Panos et al.
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
Research article
Tumour necrosis factor-α α production in fibrosing alveolitis is
macrophage subset specific
Panos Pantelidis*, Deirdre S McGrath*, Anne Marie Southcott*, Carol M Black†
and Roland M du Bois*
*Interstitial Lung Disease Unit, Department of Occupational and Environmental Medicine, Royal Brompton Hospital & National Heart and Lung Institute,
London, UK
†Department of Rheumatology, Royal Free Hospital & School of Medicine, London, UK
Correspondence: Professor RM du Bois, Interstitial Lung Disease Unit, Department of Occupational and Environmental Medicine, Royal Brompton
Hospital, London, England, SW3 6LR. Tel: +44 20 7351 8327; fax: +44 20 7351 8336; e-mail: r.dubois@rbh.nthames.nhs.uk
Introduction
TNF-α is a potent proinflammatory mediator that can mod-
ulate the function and development of most nucleated
cells, including those involved in chronic inflammatory lung
disease [1–5]. A number of studies involving animal
models and also human disease have demonstrated that
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TNF-α is upregulated in fibrosing alveolitis [6,7]. Further-
more, blockade of the effects of TNF-α with specific
blocking strategies in animal models results in the preven-
tion of inflammation and subsequent fibrosis [8–10].
SSc is a rheumatological disease of unknown aetiology in
which lung fibrosis occurs in the majority of patients
causing morbidity and increased mortality rates. Studies
from our group have previously demonstrated a survival
advantage for patients with FASSc by comparison with
cryptogenic fibrosing alveolitis (CFA) [11,12]. We have
also demonstrated differences in pathophysiology that
may be relevant to the difference in survival [13]. Previous
studies of TNF-α in the context of SSc have largely
focused on measurements of cytokines in serum [14].
One previous publication has explored a variety of
cytokines, including TNF-α, in bronchoalveolar lavage
(BAL) fluid [15], but there have been no previous studies
of AM and Mo secretion of the cytokines.
The hypothesis on which this study was based was that
TNF-α is upregulated at sites of disease in the lung by
comparison with peripheral blood mononuclear cells
(PBMCs). We aimed to compare TNF-α secretion from
AMs from patients with CFA and FASSc; to compare
secretory profiles of patients with FASSc and individuals
with SSc but without FA; and to assess whether AMs and
Mo from patients with FA were prone to secrete more
cytokine than the nonfibrotic group in response to a non-
specific mononuclear phagocyte trigger, lipopolysaccha-
ride. In order to ensure sensitivity and specificity of our
culture experiments, we have utilized the reverse
haemolytic plaque (RHPA) assay, which allows single cell
secretion of cytokine to be evaluated [16,17]. The technol-
ogy allows cells to be studied in isolation without the stim-
ulation of cell/cell contact and minimization of any
paracrine effects from nearby cells.
Materials and method
Reagents
Sheep erythrocytes were obtained from Serotec Ltd
(Oxford, UK). Recombinant protein A and endotoxin-free
bovine serum albumin were from Calbiochem-
Novabiochem Ltd (Nottingham, UK). Trypan blue 0.4%
solution, endotoxin free poly-l-lysine (molecular weight
>300,000), endotoxin-free histopaque 1077, polymyxin B
sulphate, lipopolysaccharide from Escherichia coli
055:B5, glutaraldehyde (grade I; 25% aqueous solution),
and levamisole were obtained from Sigma Chemical Co.
Ltd (Dorset, UK). The complete media consisted of RPMI
1640 containing penicillin (100 U/ml)/streptomycin
(100 µg/ml), and 0.1% (w/v) endotoxin-free bovine serum
albumin. The polyclonal rabbit antihuman TNF-α and
recombinant TNF-α (specific activity = 2 × 107 U/mg)
were from Genzyme Diagnostics (Cambridge, UK). The
monoclonal antibodies RFD1, RFD7 and RFD9 were
kindly provided by Dr LW Poulter (London, UK) and the
monoclonal antibody KP1 was kindly donated by Dr DY
Mason (Oxford, UK). All immunocytochemical reagents
including the rabbit antimouse polyclonal antibody, mouse
monoclonal alkaline phosphatase/antialkaline phosphatase
(APAAP) complex, New Fuchsin substrate and control
sera were from Dako Ltd (Bucks, UK).
Study population
The study groups comprised 18 patients with FA (nine
patients with CFA, nine patients with FASSc), 10 patients
with SSc without lung fibrosis (SSc no FA), and 10
normal subjects. In the FASSc group, three patients were
taking prednisolone; in the CFA group, two patients were
taking prednisolone and cyclophosphamide treatment;
and in the SSc no FA group one patient was on pred-
nisolone therapy.
All CFA and SSc patients underwent clinical evaluation
including chest radiography, lung function measurements,
and thin section (3-mm section) computed tomography
assessment. Patients with SSc fulfilled the American
Rheumatism Association preliminary criteria for the diag-
nosis of SSc [18]. A diagnosis of pulmonary fibrosis in
CFA and FASSc patients was determined by typical
changes on high-resolution computed tomography [19]
and patients with SSc were classified as FASSc or SSc
no FA. Previous studies from our group and others have
confirmed the specificity and sensitivity of high-resolution
computed tomography in the diagnosis of FA [20–22].
The normal subjects studied included one current smoker
and an ex-smoker, who had stopped smoking 7 years
before lavage. All normal subjects had no evidence of pul-
monary disease. The Royal Brompton Ethics Committee
gave approval for the BAL of the normal volunteers.
Details of all subjects are summarized in Table 1.
Bronchoalveolar lavage
Fibreoptic bronchoscopy and BAL were performed using
a standardized technique. Briefly, 5 × 20 ml aliquots of
prewarmed normal saline were instilled into three subseg-
mental bronchus of right middle lobe, right lower lobe and
lingula, and aspirated immediately by gentle suction. The
cells (macrophages, lymphocytes, neutrophils and eosino-
phils) were separated from the lavage fluid by centrifuga-
tion at 200 g, 4°C for 7 min and washed twice in RPMI
1640 media containing antibiotics. Cellular concentrations
and recoveries were estimated using crystal violet staining
and cellular viability measured using trypan blue exclusion.
Following cytocentrifuge preparations (Cytospin-2;
Shandon Southern Instruments, Sewickly, PA, USA), the
remainder of the cells were pelleted and resuspended in
complete media, at a count of 1 × 106 cells/ml for use in
the RHPA. Differential cell counts were performed on 200
May-Grünwald-Giemsa stained cells. The BAL cell details
are summarized in Table 1.c
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Isolation of human peripheral blood mononuclear cells
Twenty millilitres of peripheral venous blood was collected
into heparinized containers and PBMCs were isolated on
an endotoxin-free Histopaque 1077 gradient using the
method of Boyum [23]. The PBMCs were washed three
times and resuspended at a final concentration of
2×1 0 6 cells/ml in complete media, for use in the RHPA.
Reverse haemolytic plaque assay
The assay was performed as previously described
[16,17]. In brief, confluent monolayers of protein-A-coated
sheep red blood cells (RBCs) and BAL or autologous
PBMC cells from each individual were cultured in 30 µl
chambers for 12 h, 37°C, 5% CO2 with complete media
containing 1/50 dilution of rabbit antihuman TNF-α poly-
clonal antibody alone or with 10 µg/ml lipopolysaccharide.
TNF-α secretion by individual mononuclear phagocytes
was visualized as clear plaques of lysed TNF-α/anti-TNF-
α-associated sheep RBCs around the TNF-α-secreting
cells using 1/30 dilution of guinea-pig serum as the
source of complement (Gibco, Uxbridge, UK). The viability
of the BAL and PBMC cells was evaluated using trypan
blue exclusion and of TNF-α-secreting cells identified by
immunocytochemistry.
To confirm that plaque formation was specific for TNF-α
secretion by individual cells we omitted BAL and PBMC
cells from the assay; replaced the anti-TNF-α antibody
with 1:50 normal sheep serum; omitted the complement;
used uncoated sRBCs; and preabsorbed the antibody at
4°C overnight with 1 µg/ml recombinant TNF-α. Endo-
toxin contamination was excluded by assaying secretion
in the presence of 5 µg/ml endotoxin inhibitor polymyxin
B sulphate.
Preliminary time course cultures of PBMC were performed
for 3, 6, 8, 12 and 24 h on two different occasions in order
to optimize the culture conditions with respect to easily
identifiable haemolytic plaques and cellular viability.
Immunostaining of mononuclear phagocytes
AMs and Mo were identified following the RHPA by
immunolabelling with KP1 mouse monoclonal antibody
[24]. Briefly, the monolayers were fixed with 1% glu-
taraldehyde for 30 s and permeabilized using TBS pH 7.4.
Visualization of the KP1-identifiable mononuclear phago-
cytes was achieved by immunostaining with APAAP [25]
together with new fuchsin substrate system, containing
5 mmol/l levamisole, and haematoxylin counterstaining.
Subsets of AMs were identified using the monoclonal anti-
bodies RFD1, RFD7 (available from Serotec, Oxford, UK)
and RFD9 (a kind gift from Professor LW Poulter, Royal
Free Hospital) [26].
For monoclonal antibodies RFD1 and RFD9, cell monolay-
ers were incubated with 1/5 dilution antibody in complete
Available online http://respiratory-research.com/content/2/6/365
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.media at room temperature for 30 min, washed with
complete media and fixed with 0.2% glutaraldehyde in
phosphate-buffered saline for 5 min, treated with
50 mmol/l glycine in phosphate-buffered saline for
10 min followed by APAAP staining. For the RFD7 mon-
oclonal antibody the monolayers were fixed in 4%
paraformaldehyde/7% sucrose for 10 min, treated with
50 mmol/l glycine for 10 min, and permeabilized as for
KP1. Incubation with 1/5 dilution RFD7 monoclonal anti-
body was followed by APAAP staining as described. As
a control for antibody specificity, either the primary mon-
oclonal antibody was replaced with mouse IgG1 negative
control or the secondary rabbit antimouse IgG was
replaced with normal rabbit serum. The slides were
counted at 400× magnification and 100 AMs per slide
were counted.
Single-cell tumour necrosis factor-α α quantification
Plaque areas of sRBC lysis around individual TNF-α-
secreting cells were measured using Leitz microscopy
with Apple Macintosh computer and image analysis
package (Improvision, UK). For each assay condition 25
lysed plaque areas in each of three replicate chambers
were measured. The area occupied by the TNF-α-secret-
ing cells was subtracted from the each plaque area. Only
BAL cells and PBMC samples with a viability of 87% or
more were used in the RHPA. The average TNF-α plaque
area per cell and percentage of TNF-α-secreting cells
were calculated for each chamber and the average of the
triplicate samples obtained.
A total plaque area per 100 Mo/AMs was calculated
(total plaque area = average plaque area (µm2) × per-
centage of TNF-α-secreting cells) for each of the tripli-
cate chambers per condition and the total plaque area for
each condition was expressed as the average of the tripli-
cate measurements.
The following criteria were applied when measuring
plaque area and percentage of plaque forming cells: lysis
of sRBC around the plaque forming cell had to be visible
and well defined; plaque measurement was performed on
randomly selected nonoverlapping microscope fields; only
plaques formed by single cells were counted; clusters of
Mo/AMs were not included in the counting; and plaque
counting was performed ‘blind’, without knowledge of the
cell source in the chambers.
Statistical analysis
Group data were distributed nonparametrically and com-
parisons between groups were made using the
Kruskal–Wallis test for multiple group comparisons fol-
lowed by the Mann–Whitney U test for comparisons
between two groups. Correlations were calculated using
Spearman’s rank test. P < 0.05 was considered statisti-
cally significant.
Results
Validation of the assay conditions for the identification
of TNF-α α secretion
Preliminary time course experiments using PBMCs
showed that haemolytic plaque formation was first evident
at 6 h. More easily identifiable plaques of sRBC lysis
formed by TNF-α-secreting Mo were seen after 12 h incu-
bation and the viability of the PBMC cells at the end of the
culture period was >93%. At 24 h, larger haemolytic
plaques were seen but cellular viability was reduced to
<70%. For subsequent experiments, therefore, cultures
were continued for 12 h and cellular viability monitored.
Plaque formation was specific for TNF-α secretion
because no plaques were seen when the antibody was
replaced with normal sheep serum, the complement was
omitted, uncoated sRBC were used, or the antibody was
preabsorbed with recombinant TNF-α. KP1 immunostain-
ing for mononuclear phagocytes confirmed that all plaque-
forming cells were Mo or AMs.
Average levels of TNF-α α secretion by alveolar
macrophages and monocytes
In order to assess whether there is increased TNF-α pro-
duction and secretion by individual mononuclear phago-
cytes in subjects with FA we assessed the average levels
of TNF-α secretion by Mo and AMs from subjects with FA
and compared these with cells obtained from patients with
SSc without fibrosis, and normal individuals.
We observed that there was a significant difference
between the groups in the average levels of TNF-α secre-
tion by AMs (P = 0.011) but not Mo (Table 2). Specifically,
AMs from patients with FA produced more TNF-α than
subjects with SSc no FA (P = 0.008) and normal individu-
als (P = 0.009). There was no difference between CFA
and FASSc. In SSc, no significant difference in average
TNF-α level was found between those with or without FA.
Lipopolysaccharide stimulation resulted in an increase in
the average levels of TNF-α secretion per cell by Mo and
AMs from all groups of subjects examined. There
remained no differences in secretion by Mo between the
groups. The differential between the AM groups remained,
although at a higher level of secretion. Paired analysis
showed that AMs consistently secreted more TNF-α than
autologous Mo both spontaneously and after lipopolysac-
charide stimulation.
Heterogeneity of TNF-α α secretion
In order to assess whether TNF-α was a constitutive
product of all or only a subset of mononuclear phago-
cytes, we used the RHPA to enumerate the numbers of
TNF-α-secreting cells and the levels of secretion by indi-
vidual cells. Interestingly, we observed that the secretion
of TNF-α by Mo and AMs is heterogeneous and that not
all Mo and AMs secrete TNF-α. Furthermore, of the Mo
Respiratory Research    Vol 2 No 6 Pantelidis et al.and AMs that secrete TNF-α, the levels of TNF-α secretion
varied considerably between cells.
Fig. 1 illustrates the variation in the levels of TNF-α secre-
tion by mononuclear phagocytes from a patient with
FASSc in a single RHPA. Plaques of sRBC lysis formed
by Mo and AMs spontaneously secreting TNF-α over 12-h
culture in the RHPA were grouped according to plaque
size, and Fig. 1 shows the frequency distribution of these
plaque sizes. The range of plaque sizes produced by Mo
was more compact than those produced by autologous
AMs. In this regard, 7% of AMs produced plaques
>1500 µm2 area whereas no Mo produced a plaque
larger than 1500 µm2. Similar results were obtained with
Mo and AMs from subjects with CFA, SSc no FA, and
normal individuals (data not shown).
Percentages of lung and blood cells secreting TNF-α α
In order to quantify the functional heterogeneity of
mononuclear phagocytic TNF-α secretion, the percent-
ages of Mo and AMs secreting TNF-α either sponta-
neously or after lipopolysaccharide stimulation were
evaluated for all study groups.
A striking difference was observed between the percent-
ages of AMs from subjects with FA that secreted TNF-α,
and the percentages seen with cells from subjects with
SSc no FA (spontaneous P = 0.007; lipopolysaccharide
P = 0.0014) or normal individuals (spontaneous
P = 0.0011; lipopolysaccharide P = 0.0012). No differ-
ences were seen between CFA and FASSc but patients
with SSc and fibrosis were significantly different from the
group with SSc but without fibrosis (P = 0.007, sponta-
neous; P = 0.005 after lipopolysaccharide). There were no
significant differences in monocyte numbers secreting
either spontaneously or after lipopolysaccharide stimula-
tion across the groups, and consistently more
macrophages were secretors by comparison with autolo-
gous monocytes (P < 0.002).
Total secretion of TNF-α α by mononuclear phagocytes
Total  amounts of TNF-α secretion by populations of
mononuclear phagocytes is dependent on the sum of the
levels of secretion per cell and the number of Mo and AMs
secreting TNF-α. In order to evaluate the total levels of TNF-
α secretion by these two cell populations we calculated the
Available online http://respiratory-research.com/content/2/6/365
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Table 2
Median values (ranges) of spontaneous and lipopolysaccharide-induced tumour necrosis factor-α secretion
FA SSc no FA Normal
Without LPS With LPS Without LPS With LPS Without LPS With LPS
AM
APA (µm2) 1325 1500 1173 1327 1184 1377 
(1077–2240) (1277–2281) (914–1326) (1230–1586) (1024–1332) (1186–1572)
%PFC 19.8 23.7 12.5 17.7 12.0 16.5 
(12.0–30.6) (18–32) (8–14) (14–22) (9–18.7) (14–21.3)
TPA (µm2) 25225 36722 14225 25657 14829 24011 
(14532–56009) (24928–69498) (7500–18564) (17836–30807) (9783–22507) (16604–31480)
Mo
APA (µm2) 983 1251 1013  1247  1042  1222 
(789–1445) (998–1550) (864–1277) (1022–1363) (742–1220) (897–1369)
%PFC 9.3 18 9.7  16.4  10 18 
(6–13) (10–26) (7.6–13) (14–22) (6–13) (14–21.6)
TPA (µm2) 9638 23271 10007  21158 9638 20546 
(5118–13960) (15444–41000) (7200–14800) (14310–27650) (6576–13980) (12558–28651)
AM = alveolar macrophages; APA = average plaque area; FA = fibrosing alveolitis; LPS = lipopolysaccharide; Mo = peripheral blood monocytes;
%PFC = percentage of plaque forming cells; SSc = systemic sclerosis; TPA = Total plaque area.
Figure 1
Heterogeneity of tumour necrosis factor (TNF)-α secretion by
individual mononuclear phagocytes from a patient with systemic
sclerosis. Haemolytic plaques obtained after a 12-h culture were
assigned to size groupings. Shown are frequency distributions of the
percentages of cells with plaques of different areas. AM = alveolar
macrophages; Mo = monocytes.product of the average levels of TNF-α secretion per cell
and the percentage of TNF-α-secreting mononuclear
phagocytes.
In patients with FA the spontaneous total TNF-α secretion
by AMs was significantly higher than in patients with SSc
no FA (P = 0.0002), and normal individuals (P < 0.001;
Table 2). In this regard, the median total TNF-α secretion
by AMs from patients with FA was greater than AMs from
the other groups. No differences were seen between CFA
and FASSc. AM from patients with FASSc secreted more
TNF-α than patients with no FA (P = 0.003). The total
spontaneous TNF-α secretion by Mo was not significantly
different between the groups.
Stimulation with lipopolysaccharide resulted in upregula-
tion of the total secretion of TNF-α by AMs and Mo in all
groups. On average, Mo secretion increased by 112% for
the nonfibrotic groups and 141% for FA. Similarly AM
secretion was increased by 62–80% for the nonfibrotic
groups and 46% for FA. AMs from patients with FA
secreted significantly more TNF-α than those from
patients with SSc no FA (P = 0.0012) and normal individ-
uals (P = 0.001; results not shown). We did not observe
any significant difference between the groups in the
levels of total TNF-α secretion by lipopolysaccharide
stimulated Mo.
Relationship between TNF-α α secretion and
bronchoalveolar lavage neutrophils
To show that in vitro TNF-α synthesis and secretion was
likely a true reflection of events in vivo, the relationship
between the total levels of spontaneously secreted TNF-α
and neutrophils obtained by BAL from patients with FA
was quantified. A correlation (r = 0.49;  P < 0.04) was
found, suggesting that one of the consequences of AM
TNF-α secretion is neutrophil influx into the lungs of
patients with FA. However, other mediators may also be
involved in neutrophil chemotaxis.
Immunophenotype and morphology of the TNF-α α-
secreting alveolar macrophages
Having established that there is heterogeneity in the
secretion of TNF-α by mononuclear phagocytes and that
in subjects with FA there is an increase in the percentage
of TNF-α-secreting AMs, we set out to characterize the
phenotype of the TNF-α-secreting AMs. We evaluated the
phenotype of the TNF-α-secreting AMs from subjects with
FA, SSc no FA and normals, by cell size and by using the
monoclonal antibodies RFD1, RFD7 and RFD9 following
culture in the RHPA.
Production was proportional to cell diameter for AMs
(r = 0.66; P < 0.001) but not for Mo (r = 0.1; P = 0.63).
AMs from six patients with FA (CFA, n = 4; FASSc, n = 2),
three patients with SSc no FA and three normal individu-
als were evaluated using the RFD panel of monoclonal
antibodies. All subjects underwent staining for all the
subsets. Of the TNF-α-secreting AMs, the largest subset
was that recognized by the monoclonal antibody RFD7
(FA, 81.3 ± 15.4%; SSc no FA, 82.7 ± 8.8%; normals,
90.4 ± 4.4%; mean ± SEM), whereas lower percentages
expressed the ligands identified by the monoclonal anti-
bodies RFD1 and RFD9 (Fig. 2A). We observed that only
a minority of AMs that were identified by the RFD mono-
clonal antibodies secreted TNF-α (Fig. 2B). In this regard,
for all populations studied, TNF-α was secreted by, on
average, 28 ± 5.3% of the RFD7-positive cells,
5.1 ± 1.1% of the RFD9-positive cells, and 13.2 ± 3.9%
of the RFD1-positive cells. The total percentages of AMs
that were identified by these monoclonal antibodies was
greater than 100% in the FA group, indicating that there is
a population of AMs expressing more than one epitope.
Discussion
This study has demonstrated that AMs from patients with
FA secrete more TNF-α per cell than patients with SSc
without FA and normal individuals. We further demon-
strated that the percentages of cells secreting TNF-α is
higher in FA than in the other groups, and thus the total
TNF secretion is significantly higher in FA. In contrast,
there are no differences in secretion between the groups’
peripheral blood monocytes. The difference in TNF-α pro-
duction between AMs and peripheral blood monocytes
probably reflects monocyte maturation and localised acti-
vation. Lipopolysaccharide stimulation generally upregu-
lated secretion in all groups, maintaining the differential
between the groups. We demonstrated no difference
between cells obtained from patients with CFA and those
with FASSc, but differences between FASSc and SSc no
FA were similar to those seen in comparisons of the FA
group as a whole with the non-FA group. Furthermore, the
TNF values for those receiving treatment did not demon-
strate a skewed distribution when compared with the
other populations (data not included). Finally, we demon-
strated that there were significant heterogeneity of TNF-α
secretion and that a specific subset of mononuclear
phagocytes, RFD7, was responsible for more than 80% of
TNF production.
This study differs from previous studies in SSc by demon-
strating a specific subset of AMs responsible for the bulk
of local TNF production. Studies looking at BAL fluid do
not have the power to identify the cell source of TNF-α
production and by doing so we open up an opportunity for
much more specific targeting of anti-TNF-α approaches.
The use of monoclonal antibodies in rheumatoid arthritis
has been successful in minimising human chronic inflam-
matory disease [27,28]. By demonstrating the primary cell
source of TNF-α in FASSc, more targeted, possibly local,
anti-TNF strategies might be employed with success in
the future.
Respiratory Research    Vol 2 No 6 Pantelidis et al.The study has shown clearly that it is only when mono-
nuclear phagocytes have matured in the lung into tissue-
type AMs that an enhanced TNF-α secretion occurs. The
trigger for this upregulation is unknown, although, in previ-
ous studies, we have demonstrated that AMs from
patients with FASSc and CFA secrete enhanced amounts
of interleukin-8, a known TNF-α upregulator in addition to
its chemokine functions [16]. Equally possible is that the
primary trigger for FASSc, at present unknown, directly
stimulates mononuclear phagocytes in the local micro-
environment.
The advantages of using the RHPA over more traditional
culture methodologies are multiple. Firstly, cells can be
studied in isolation which removes the potential confound-
ing affects of cell/cell contact and minimizes, because of
the small (30–40 µl culture chamber volume) paracrine
effects. Secondly, the identity of the subset of cells pro-
ducing TNF-α can be established after the culture period.
Thirdly, by specific blocking experiments we can confirm
conclusively that the effects are due to TNF-α. Consistent
with the increased sensitivity and specificity of this tech-
nique, we have previously demonstrated an enhanced
secretion of interleukin-8 by AMs from patients with FA
[16]. In that study, by contrast with this study, autologous
PBMCs secreted enhanced amounts of interleukin-8 by
comparison with AMs. It was only in the FA group that
enhanced interleukin-8 production was seen from AMs.
Furthermore, in the interleukin-8 study, we showed that
the enhanced secretion was exclusively due to an increase
in the percentage of AMs secreting interleukin-8 and that
the cell source was the less mature monocytoid AMs.
Enhanced TNF-α secretion has been demonstrated in this
study to be due to a combination of increased average
amounts of product from each cell as well as an increase
in the numbers of cells secreting TNF-α. This is an addi-
tional advantage of this technology, demonstrating stimu-
lation of cells already secreting TNF-α as well as
recruitment of new TNF-α secretors.
In more traditional culture environments, much larger
numbers of cells are needed, they are often in cell/cell
contact, and the conditioned medium contains a ‘soup’ of
other cytokines that have variable regulatory effects on the
cells of interest. However, in vivo, it is likely that very small
amounts of cytokine operate in tight microenvironmental
conditions. The alternative is that the unfettered actions of
cytokines will cause more host damage than host defence
modulation. The RHPA closely reproduces these condi-
tions, providing more realistic information than previous
techniques on events in the local environment.
One criticism of this study is that the results of the
immunophenotyping are limited by the small number of
subjects studied (CFA, n = 4; FASSc, n = 2; SSc no FA,
n = 3; normal, n = 3). At the time of the study, the com-
plexity of the technique and the post-RHPA treatment
required for immunostaining with the RFD antibody panel
meant that only some of the slides available were suitable
for subpopulation analysis. However, the RFD monoclonal
antibodies identified proportionately the same percentage
of cells in all 12 patients irrespective of group, and in all
individuals the TNF-α secreting cells were stained with
RFD7 monoclonal antibody. It would appear, therefore,
that there are no significant subpopulation differences
with regard to TNF-α secretion across the groups and that
a number of 12 is an acceptable cohort. This is similar to
our findings with regard to interleukin-8 secretion [29].
Conclusion
TNF-α remains a crucial cytokine in inflammatory
responses. Involved in defence against microbes and
other foreign agents, there is also little doubt that
Available online http://respiratory-research.com/content/2/6/365
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Figure 2
Immunophenotyping of tumour necrosis factor (TNF)-α-secreting
alveolar macrophages (AMs). (A) Shown are the percentages of
tumour necrosis factor-α-secreting AMs from patients with systemic
sclerosis (SSc) without fibrosing alveolitis (FA), patients with FA and
normal individuals (Norm) that were identified by the monoclonal
antibodies (mAbs) RFD1, RFD7 and RFD9 (the data are presented as
means ± SEM). (B) Shown are the average absolute percentages of
AMs from each subject group identified by the mAbs RFD1, RFD7 and
RFD9. The solid areas under each bar represent the percentage of
each RFD-identified AM population that was secreting TNF-α.enhanced TNF-α secretion is responsible for releasing a
cascade of subsequent mediator secretion resulting in
chronic, persistent inflammation, lung injury and subse-
quent fibrosis [30]. Targeted approaches to therapy in the
future will necessitate the identification of key cytokines
that operate early in the pathophysiology of a disease to
make more logical specific targeting approaches. TNF-α
has been demonstrated previously to be such a cytokine
[28]. Zhang et al. [10] showed in a series of animal experi-
ments that blockade of TNF-α, either before or after the
triggering of fibrosis, abrogates subsequent chronic
inflammation and fibrosis.
In this study we have demonstrated that TNF-α is upregu-
lated specifically in the lungs of patients with FASSc and
that a single subset of macrophages is responsible for the
bulk of the secretion. In conclusion, we suggest that this
may indicate a role for specific TNF-α blockade as a thera-
peutic strategy in the FA of SSc.
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